Bli medlem
Bli medlem

Du är här


Herantis Pharma Oyj: Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC

Herantis Pharma Plc's directed share issue and share subscription by Broadview
Ventures I, LLC

Herantis Pharma Plc
Stock exchange release 14 January 2016, 10:00 am

The Board of Directors of Herantis Pharma Plc has decided on a directed share
issue to Broadview Ventures I, LLC based on authorization by the company's
annual meeting of shareholders and according to a subscription agreement
between the parties. Broadview Ventures I, LLC has fully subscribed to this
share issue, total of 32,311 new shares in Herantis Pharma Plc for a
subscription price of EUR 10.00 per share.

The new shares have been registered in the Trade Register on 12 January 2016,
as of which date the new shares will establish shareholder rights.

The share capital will not increase with subscriptions. The entire
subscription price of EUR 323,110.00 will be entered in the invested
unrestricted equity reserve of the company. As a result of the share
subscriptions, the number of shares of Herantis Pharma Plc will increase to

The new shares will be traded on the NASDAQ OMX Helsinki Ltd's First North
marketplace together with the old shares as of today, 14 January 2016.

Share information of the Herantis Pharma Plc share after the registration of
the new shares:

Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 4,118,305
Share Capital: 80,000.00 euro

Herantis Pharma Plc.
Pekka Simula

Further information:

Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web

Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

About Herantis Pharma Plc

Herantis Pharma Plc is a pharmaceutical company specialised in new drug
research and development. The company focuses on diseases with an unmet
clinical need. These diseases include for example Parkinson's disease and
secondary lymphedema. The shares of Herantis are listed on the First North
Finland marketplace run by Nasdaq Helsinki stock exchange.


Nasdaq Helsinki
Main media


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.